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The b-galactoside-binding protein galectin-9 is crit-
ical in regulating the immune response, but the
mechanism by which it functions remains unclear.
We have demonstrated that galectin-9 is highly
expressed by induced regulatory T cells (iTreg) and
was crucial for the generation and function of iTreg
cells, but not natural regulatory T (nTreg) cells. Galec-
tin-9 expression within iTreg cells was driven by the
transcription factor Smad3, forming a feed-forward
loop, which further promoted Foxp3 expression.
Galectin-9 increased iTreg cell stability and function
by directly binding to its receptor CD44, which
formed a complex with transforming growth factor-b
(TGF-b) receptor I (TGF-bRI), and activated Smad3.
Galectin-9 signaling was further found to regulate
iTreg cell induction by dominantly acting through
the CNS1 region of the Foxp3 locus. Our data sug-
gest that exogenous galectin-9, in addition to being
an effector molecule for Treg cells, acts synergisti-
cally with TGF-b to enforce iTreg cell differentiation
and maintenance.
INTRODUCTION
The role of Foxp3+ regulatory T (Treg) cells in immune tolerance
and homeostasis has been extensively studied. Treg cells
comprise a specific T cell lineage, which can suppress effector
T cell responses during infection, inflammation, and autoimmu-
nity (Josefowicz et al., 2012a; Sakaguchi et al., 2010). As a mas-
ter transcription factor of Treg cells, Foxp3 plays a critical role in
their development and regulates a wide spectrum of Treg cell
functions (Sakaguchi et al., 2010; Zheng and Rudensky, 2007).
At least two different types of Foxp3+ Treg cells have been
defined. Natural Treg (nTreg) cells develop in the thymus and
recognize self-antigen with intermediate affinity, leading to their
differentiation toward regulatory cells. In contrast, adaptive or
induced Treg (iTreg) cells can differentiate from naive T cells in270 Immunity 41, 270–282, August 21, 2014 ª2014 Elsevier Inc.the periphery and are especially important in regulating immune
responses and autoimmunity in the gut (Bluestone and Abbas,
2003; Josefowicz et al., 2012b). Both of these Treg cell subsets
express Foxp3. Previous studies have shown that the expression
of Foxp3 mainly depends on transforming growth factor-b re-
ceptor (TGF-bR) and interleukin-2 receptor (IL-2R) signaling
(Fontenot et al., 2005; Kim et al., 2005; Ouyang et al., 2010).
While TGF-b is critical for induction of Foxp3 expression, IL-2
supports the growth of iTreg cells. Loss of either TGF-b or IL-2
signaling results in a defect in Treg cell generation. TGF-b
signaling largely activates Smad proteins, transcription factors
known to promote the induction of a number of molecules
required for Treg cell generation including Foxp3 (Ruan et al.,
2009; Tone et al., 2008). The activation of TGF-bR directly trig-
gers the phosphorylation and nuclear translocation of recep-
tor-regulated Smad proteins, which subsequently mediate their
binding to the Foxp3 locus, leading to the transactivation of
Foxp3 expression (Lagna et al., 1996; Liu et al., 1997; Macı´as-
Silva et al., 1996; Massague´, 1998). Moreover, besides the tran-
scriptional regulation of Foxp3, activation of Smad3 induces
appropriate histone modifications, which result in the promotion
and stabilization of the Foxp3 polypeptide (Ohkura et al., 2012;
Toker and Huehn, 2011). A recent study demonstrates a critical
role of noncoding DNA elements in the Foxp3 locus for the Treg
cell lineage commitment, and epigenome-dependent regulation
of these regions largely determines the function and stability of
natural or induced Treg cells (Zheng et al., 2010).
Galectin-9 (encoded by Lgals9) is a member of the tandem-
repeat group of galectins with multiple biological functions
such as chemoattraction, cell aggregation, and apoptosis
(Alam et al., 2011; Rabinovich and Toscano, 2009). It is localized
on the cell membrane, in the cytoplasm and nucleus (Hirashima
et al., 2004). In vivo treatment with galectin-9 leads to the sup-
pression of proinflammatory cytokines and an increase of Treg
cells (Arikawa et al., 2009). Moreover, recent studies also indi-
cate that administration of exogenous galectin-9 can regulate
Th17 and Treg cell development (Kared et al., 2013; Oomizu
et al., 2012). However, the precise molecular mechanism by
which galectin-9 regulates Foxp3+ Treg cell differentiation is still
largely unknown.
We and others have previously identified galectin-9 as a ligand
for Tim-3, a T helper-1 (Th1) cell-specific type 1 membrane
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lating effector Th1 cell responses (Zhu et al., 2005). Besides
Tim-3, CD44 is another known cell surface molecule that can
potentially interact with galectin-9 (Bollyky et al., 2009; Bourgui-
gnon et al., 2002; Liu et al., 2009; Tanikawa et al., 2010). CD44 is
a highly glycosylated cell-adhesion molecule, which binds not
only to galectin-9 but also to hyaluronic acid (HA). It has been re-
ported that galectin-9 can bind to CD44 and regulate leukocyte
migration during allergic lung inflammation via modulation of
CD44-HA interactions (Katoh et al., 2007; Nagahara et al., 2008).
In this study, by utilizing galectin-9-deficient mice, we have
demonstrated that the genetic loss of galectin-9 leads to a
reduction in Foxp3 expression and suppressor function of
iTreg cells both in vitro and in vivo. We also have shown that ga-
lectin-9 synergizes with TGF-b to promote Foxp3 expression by
interacting with a CD44-TGF-bRI complex. This interaction pro-
moted not only the expression but also the stability of Foxp3,
leading to enhanced suppressive function in iTreg cells. More-
over, galectin-9 signaling regulated iTreg generation via the
CNS1 region of the Foxp3 genomic locus. Our results reveal a
positive feed-forward loop employed by iTreg cells, which in-
volves galectin-9-driven upregulation of Foxp3, which in turn
strengthens the iTreg cell phenotype.
RESULTS
Galectin-9 Deficiency Reduces iTreg, but Not nTreg,
Cells
It has been previously reported that administration of galectin-9
promotes Treg cell numbers during the development of
collagen-induced arthritis (CIA) (Arikawa et al., 2009; Seki
et al., 2008), suggesting that galectin-9 might play an important
role in Treg cell development in vivo. By employing galectin-9-
deficient (Lgals9–/–) mice, we first found normal T cell develop-
ment in thymus, spleen, and lymph nodes (LN) in these mice
(data not shown).
Under either steady state or inflammatory conditions, iTreg
cells have been described to be generated and accumulate
mainly in the gut (Coombes et al., 2007; Siddiqui and Powrie,
2008; Sun et al., 2007). Although we found a similar number of
Foxp3+ Treg cells in the mesenteric LN (mLN), the cells isolated
from the lamina propria (LP) of Lgals9–/– mice showed a lower
frequency of Treg cells compared to WT littermates (Figures
1A; see Figure S1A available online). Neuropilin 1 (Nrp1) has
been recently described as a surfacemarker to distinguish nTreg
cells from iTreg cells (Weiss et al., 2012; Yadav et al., 2012). We
thus analyzed the nTreg and iTreg population in the small bowel
and found a lower frequency of Nrp1loFoxp3+ iTreg cells in LP of
galectin-9 deficient mice, whereas there was no difference in
Nrp1hiFoxp3+ nTreg cells between WT and Lgals9–/– mice (Fig-
ures 1B and S1B). These data suggest a defect in iTreg differen-
tiation in the absence of galectin-9 in vivo.
During in vitro differentiation, Lgals9–/– T cells displayed
impaired Foxp3 expression (Figure 1C). Addition of exogenous
galectin-9 alone induced amodest increase in Foxp3 expression
in activated naive T cells, whereas we observed a substantial
synergistic effect of galectin-9 with TGF-b in inducing Foxp3
expression. Furthermore, the exogenous addition of galectin-9
with TGF-b restored Foxp3 expression in Lgals9–/– iTreg cells(Figure 1C). We also discovered that galectin-9 promoted iTreg
cells differentiation in a carbohydrate-dependent manner in
that additional lactose, which breaks the b-galactoside bond of
galectin-9, inhibited iTreg cell generation by TGF-b and galec-
tin-9 (Figure S1C). Furthermore, this galectin-9 dependent effect
was specific for iTreg cell differentiation, as we could not detect
any defects of differentiation within other T cell subsets (data not
shown). Overall, these results suggest that galectin-9 facilitates
the expression of Foxp3 during iTreg cell differentiation both
in vivo and in vitro.
Galectin-9 Extrinsically Regulates the Generation
of iTreg Cells
We next asked whether such production of galectin-9 could
function as an intrinsic or extrinsic mechanism for iTreg cell dif-
ferentiation. We polarized CD45.1+ WT and CD45.2+ Lgals9–/–
T cells in the presence of TGF-b either separately or together.
The difference of Foxp3 expression between WT and Lgals9–/–
T cells was diminished when the two types of cells were cultured
together (Figures 1D and 1E). A similar phenotype was also
observed in vivo. Ten weeks after reconstitution of congenic
CD45.1 Lgals9–/– host mice with either WT or galectin-9-defi-
cient (CD45.2) bone marrow (BM), we observed reduced Treg
cells in LP with Lgals9–/– BM when compared to the WT BM chi-
meras (Figures S1D and S1E). However, when WT mice were
used as hosts, where galectin-9 is present exogenously, Treg
cells in different organs was found to be comparable (Figures
S1F and S1G). To better understand whether the lack of galec-
tin-9 could specifically impair iTreg cell generation in vivo, we
employed a model of ovalbumin (OVA)-induced generation of
iTreg cells (Coombes et al., 2007). We generated Lgals9–/–
OVA specific T cells by crossing Lgals9–/– mice with Rag2–/–
OT-II mice. OVA-specific T cells purified from these mice were
transferred into congenic CD45.1 Lgals9–/– recipient mice. In
response to the administration of OVA as a specific oral antigen,
the frequency of Foxp3+ iTreg cells in the CD45.2+ donor cell
compartment isolated from Peyer’s patches (PP) and LP was
lower in the absence of galectin-9 compared to the frequency
observed after WT cell transfer (Figures 1F and S1H). However,
this difference was blunted when we transferred the cells into
WT recipient mice (Figures 1G and S1I). Taken together, these
data suggest that galectin-9 specifically promotes the genera-
tion of iTreg cells both in vitro and in vivo via a cell-extrinsic
mechanism.
Smad3 Regulates Galectin-9 during iTreg Cell
Differentiation
Galectin-9 is a ubiquitously expressed protein and has been
found to be upregulated upon activation in various immune cells
(Liu and Rabinovich, 2010; Vasta, 2009). We found that CD4+
T cells expressed higher galectin-9 (Figure S2A). Next we deter-
mined Lgals9 expression by quantitative PCR (qPCR) more spe-
cifically in different CD4+ T cell subsets. We noticed that Lgals9
messenger RNA (mRNA) and protein expression were both
higher in iTreg cells than the other T cell subsets, including nTreg
cells (Figures 2A and 2B). We further found that galectin-9 was
expressed as early as 12 hr after activation in the presence of
TGF-b, and its mRNA and protein expression were sustained
high throughout iTreg cell differentiation (Figures S2B andImmunity 41, 270–282, August 21, 2014 ª2014 Elsevier Inc. 271
Figure 1. Galectin-9 Promotes Foxp3 Expression during iTreg Cell Differentiation
(A) The percentage of Foxp3+ Treg cells in mesenteric LN (mLN) and lamina propria (LP) was determined by flow cytometry.
(B) Flow cytometry analysis of CD4+ T cells from the LP of WT or Lgals9–/– mice is shown.
(C) Activated naive CD4+ T cells were stimulated with TGF-b and/or recombinant galectin-9. The frequency of Foxp3+ cells was determined by flow cytometry.
(D and E) CD45.1+WT andCD45.2+ Lgals9–/– naive T cells were cultured (D) separately or (E) together in the presence of TGF-b. The frequency of Foxp3+ cells was
then determined by flow cytometry.
(F and G) OT-II Rag2–/– and OT-II Rag2–/–Lgals9–/–CD45.2+CD4+ T cells were transferred into congenic CD45.1 (F) Lgals9–/– or (G) WT recipient mice, followed by
administration of OVA in the drinking water for 5 days. CD45.2+Foxp3+ iTreg cells from Peyer’s patches (PP) and LP of Lgals9–/– recipient mice were determined
by flow cytometry. Data are representative of three independent experiments with nR 4 mice each group.
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pressed during TGF-b-driven iTreg cell differentiation.
The upregulation of galectin-9 in iTreg cells suggests that
there might be a positive feedforward loop activated by TGF-b
and galectin-9 to enhance the iTreg cell differentiation. It has
been previously reported that Smad3 is critical for optimal induc-
tion of Foxp3 in response to TGF-b (Takimoto et al., 2010; Xu
et al., 2010). We therefore addressed whether the activation of
Smad3 directly results in the transactivation of Lgals9. Indeed,
the chromatin immunoprecipitation (ChIP) assay showed that
Smad3 interacted with multiple binding sites in the Lgals9 pro-
moter in iTreg cells, but not in Th0 cells (Figure 2C). To determine272 Immunity 41, 270–282, August 21, 2014 ª2014 Elsevier Inc.whether Smad3 transactivates galectin-9 expression, we ex-
pressed an Lgals9 promoter luciferase reporter construct in
EL4 LAF cells, an EL4 subclone that maintains T cell activation
properties (Tone et al., 2008; Xu et al., 2010). In support of our hy-
pothesis, Smad3 transactivated the Lgals9 promoter with simul-
taneous T cell receptor (TCR) signaling in a dose-dependent
manner (Figures 2D and 2E). Retroviral overexpression of
Smad3 in WT naive T cells under Th0 and iTreg conditions
increased Foxp3 and galectin-9 mRNA, as well as protein (Fig-
ures S2D and S2E). Consistently, Smad3–/– iTreg cells exhibited
reduced expression of both Foxp3 and galectin-9 (Figures 2F
and 2G). These data provide functional evidence that Smad3
Figure 2. Smad3 Regulates Galectin-9 during iTreg Cell Differentiation
(A) Naive CD4+CD44loCD62L+CD25– T cells fromWTmice were differentiated into different T cell subsets. Quantitative real-time PCR analysis of Lgals9mRNA in
different subsets is presented relative to the expression of GAPDH mRNA.
(B) Protein expression of galectin-9 was determined in different T cell subsets by flow cytometry.
(C) The binding of Smad3 to the Lgals9 promoter in Th0 and iTreg cells was assayed by ChIP-PCR. Six horizontal bars represent the locations of Smad3 binding
sites on Lgals9 locus detected by real-time PCR.
(D and E) Luciferase assay using an Lgals9 promoter-driven reporter in EL4 LAF cells transfected with a control or Smad3-expressing vector under the indicated
conditions is shown. Promoter activity was determined 24 hr after the addition of stimuli.
(F and G) mRNA (F) and protein expression (G) amounts of Foxp3 and galectin-9 withinWT andSmad3–/– iTreg cells; Data are representative of three independent
experiments with nR 4 mice each group (A, B, F, G) or are pooled from three independent experiments (C–E). *p < 0.05 and **p < 0.01 (Student’s t test, error bars
represent SD).
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cell differentiation, generating a positive autocrine loop to further
enhance Foxp3 expression.
Lgals9–/– iTreg Cells Have Reduced Suppressive Activity
Using in vitro and in vivo approaches, multiple studies have
shown that iTreg cells are important to maintain immune homeo-
stasis and regulate effector T cells during immune responses
(Fontenot et al., 2003; Williams and Rudensky, 2007). To assess
the functionality of iTreg cells in the absence of galectin-9, we
carried out in vitro suppression assays. To this end, galectin-9-
deficient mice were crossed to the Foxp3-GFP reporter back-
ground to obtain naive CD4+ T cells and exclude GFP+ nTreg
cells from the analysis. Naive T cells (CD4+CD62L+CD44–GFP–)
from the WT and Lgals9–/– mice were differentiated in vitro into
iTreg cells for 3 days, sorted for GFP+ expression, and then
tested in functional assays (Figure S3A). Galectin-9-deficient
Foxp3+ iTreg cells exhibited lower suppressive capacity, in thatthey were less efficient in suppressing the proliferative response
of WT T effector cells (Figure 3A). The expression of a series of
costimulatory molecules expressed on iTreg cells were reduced
on Lgals9–/– iTreg cells (Figure 3B). The production of IL-10 in
iTreg cells, a well-characterized anti-inflammatory effector cyto-
kine produced by iTregs (Chaudhry et al., 2011; Rubtsov et al.,
2008), was also found to be reduced in the absence of galec-
tin-9 (Figures S3B and S3C). The reduction in regulatory function
of Lgals9–/– iTreg cells was further studied in a T cell cotransfer
colitis disease model. WT CD4+CD45RBhi cells were transferred
into Rag2–/–Lgals9–/– mice to eliminate the exogenous galec-
tin-9, together with either WT or Lgals9–/– in vitro differentiated
Foxp3+ (GFP) iTreg cells at a ratio of 5:1. Consistent with previ-
ous study (Toms et al., 2008), WT iTreg cells efficiently sup-
pressed the development of intestinal inflammation asmeasured
by weight loss, whereas galectin-9-deficient iTreg cells didn’t
protect themice from the development of a wasting disease (Fig-
ures 3C and 3D and S3D). In fact, Lgals9–/– iTreg cells failed toImmunity 41, 270–282, August 21, 2014 ª2014 Elsevier Inc. 273
Figure 3. Lgals9–/– iTreg Cells Have Reduced Suppressive Activity
(A) Proliferation of WT naive CD4+ T cells in the presence of anti-CD3 and anti-CD28 and GFP+ (Foxp3+) iTreg cells from Foxp3GFP and Foxp3GFPLgals9–/– mice.
Data shown are presented as mean [3H]-thymidine incorporation.
(B) The expression of indicated costimulatory molecules on Foxp3GFP and Foxp3GFPLgals9–/– CD4+GFP+ iTreg cells was determined by flow cytometry.
(C) Body weight of Rag2–/–Lgals9–/– mice transferred with WT CD4+CD25CD45RBhi T cells with or without WT or Lgals9–/– Foxp3+ (GFP) iTreg cells.
(D) Hematoxylin and eosin staining of colon samples from the different groups as in (C) (original magnification, 3 20).
(E) Flow cytometry of IL-17 and IFN-g secretion by CD4+ T cells isolated from spleen and LP from indicated groups as in (C) 10 weeks after colitis induction. The
data are representative of three independent experiments with nR 4 mice each group. *p < 0.05 (Student’s t test, error bars represent SD).
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litis (Figure 3E). These data suggest that galectin-9 promotes
iTreg cell suppressive function and potentially prevents them
from developing into effector T cells.
Galectin-9 Enhances iTreg Cell Stability
To address the role of galectin-9 in mediating the stability of iTreg
cells,we transferredpurified in vitrodifferentiatedGFP+ iTregcells
from WT or Lgals9–/– mice into Rag2–/–Lgals9–/– mice. We
analyzed the presence of Foxp3+ (GFP) cells 2 and 5 days after
transfer and found that there was a lower frequency of Foxp3+
cells in recipients of Lgals9–/– donor cells (Figure 4A). We further
found that Lgals9–/– iTreg cells preferentially converted into inter-
feron-g (IFN-g) but not IL-17-producing cells, when compared to
WT iTreg (Figure 4B). These results implicate that the loss of
galectin-9 could impair iTreg cell stability and that thesecells pref-
erentially acquire a Th1 cell phenotype in vivo. To further assess274 Immunity 41, 270–282, August 21, 2014 ª2014 Elsevier Inc.the correlation of galectin-9 and iTregcell fate,we tookadvantage
of a Foxp3 fate-mapping (FM) mouse by crossing the Foxp3Cre
(Foxp3-YFP-Cre) mice (Zheng et al., 2009) with Rosa26RFP
(Rosa26 genetically targeted of loxP-stop-loxP-tdTomato) mice.
In thismouse,YFPexpression issynchronizedwithFoxp3expres-
sion, and Cre activity is monitored by RFP from the Rosa26 pro-
moter. Thus, this allowed us to visualize cells that have initiated
the Foxp3 program (RFP) regardless of their present production
of this protein. We then transferred CD4+CD45RBhiYFP–RFP–
cells from WT or Lgals9–/– FM mice into Rag2–/–Lgals9–/– mice to
induce colitis. Lgals9–/– FM cells induced enhanced develop-
ment of intestinal inflammation (Figures 4C and S4A). A stronger
Th1 cell response and a reduced frequency of Treg (CD4+RFP+
and CD4+RFP+YFP+) cells were observed in the gut within the
Lgals9–/– FM mice 10 weeks after transfer (Figures 4D and S4B).
More importantly, there was a dramatic loss of YFP+ T cells in
the Lgals9–/– FM mice, indicating the iTreg cells could not
Figure 4. Galectin-9 Enhances iTreg Cell Stability
(A) Purified GFP+ iTreg from Foxp3GFP and Foxp3GFPLgals9–/– mice were intravenously transferred into Rag2–/–Lgals9–/– recipient mice. Two and 5 days after
transfer, frequency of GFP+ cells were determined by flow cytometry.
(B) IL-17 and IFN-g production in the GFP– fraction in (A) were determined by flow cytometry.
(C) Body weight of Rag2–/–Lgals9–/– mice transferred i.p. with CD4+CD25CD45RBhiRFP–YFP– T cells from WT or Lgals9–/– FM mice.
(D) Flow cytometry of IL-17 and IFN-g, YFP, and RFP expression by CD4+ T cells isolated from LP from indicated groups as in (C) 10 weeks after colitis induction.
The data are representative of three independent experiments with nR 5 mice each group. *p < 0.05 (Student’s t test, error bars represent SD).
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absence of galectin-9 (Figures S4C and S4D).
CD44 Mediates Galectin-9 Signaling during iTreg Cell
Differentiation
Tim-3 and CD44 have been both described as the receptors for
galectin-9 on various cell types (Bourguignon et al., 2002; Chou
et al., 2009; Katoh et al., 2007; Tanikawa et al., 2010; Wang et al.,
2009; Zhu et al., 2005). We first found that Tim-3 was expressed
on Th1, but not iTreg cells. In contrast, CD44 was observed to be
highly expressed on both Th1 and iTreg cells in vitro (Figures S5A
and S5B). We also showed here the protein-protein interaction
between galectin-9 and its receptor CD44 on the differentiated
iTreg cells (Figure S5C). It has been shown that in breast cancer
cells, CD44 forms a complex with TGF-b receptor I (TGF-bRI),
and in this setting the CD44 ligand HA can function as a cosignal
enhancing the activity of TGF-bRI (Bourguignon et al., 2002).
After 3 days culture with TGF-b, we found increased recruitment
and coclustering of TGF-bRI and CD44 on WT but not Lgals9–/–
iTreg cells (Figure 5A). In WT iTregs, CD44 and TGF-bRI inter-
acted with each other to form a complex (Figure 5B). In situ prox-
imity ligation assay (PLA) confirmed the interaction of TGF-bRI
and CD44 as evidenced by the presence of multiple associated
dots appearing on the iTreg cell membrane (Figure 5C). As a
consequence of such association, kinase activity of TGF-bRI in
WT T cells was induced by TGF-b stimulation, which was further
promoted by synergistic stimulation with galectin-9 while suchactivity was significantly reduced in Cd44–/– iTregs cells (Fig-
ure 5D). These data suggest that CD44 functions as one of the
galectin-9 receptors on iTreg cells, transducing the signal from
galectin-9 via a heterodimer complex of CD44-TGF-bRI.
The CNS1 Region Is Crucial for Mediating the Galectin-9
Signal within iTreg, but Not nTreg, Cells
It has been described that Smad3 functions as a direct down-
stream target of TGF-bRI signaling (Takimoto et al., 2010; Xu
et al., 2010). Immunoblot showed that phosphorylation of
Smad3 was reduced in galectin-9-deficient T cells upon TGF-b
stimulation compared with WT T cells (Figure S6A). It has been
reported that the expression and stability of Foxp3 is dependent
on a core promoter and several evolutionarily conserved non-
coding sequences (CNS) at the Foxp3 locus (Zheng et al.,
2010). The Smad3 binding site is harbored in the CNS1 region
and has been shown to be critical for Foxp3 induction in iTreg
cells (Tone et al., 2008). ChIP assays showed that Smad3 inter-
action with the CNS1 region is reduced in Lgals9–/– iTreg cells
(Figure S6B). An accessible CNS1 region is associated with
acetylated histones and considered as an enhancer for Foxp3
induction. ChIP analysis of acetylated histone H4 (AcH4)
showed lower AcH4 modifications at the CNS1 site in Lgals9–/–
iTreg cells, correlating with the Foxp3 expression (Figures 6A
and S6C). Nevertheless, histone modification is rather a dy-
namic process than a poised status. We therefore analyzed
Foxp3 mRNA at different time points under various iTregImmunity 41, 270–282, August 21, 2014 ª2014 Elsevier Inc. 275
Figure 5. CD44 Mediates Galectin-9 Signaling during iTreg Differentiation
(A) Confocal images of WT or Lgals9–/– Th0 and iTreg cells stained with anti-TGF-bRI and anti-CD44 antibodies.
(B) Immunoprecipitation (with control immunoglobulin G, anti-TGF-bRI, or anti-CD44) of lysates of WT and Cd44–/– iTreg cells, followed by immunoblot analysis
with the indicated antibodies.
(C) TGF-bRI and CD44 association was visualized in iTreg cells with an in situ proximity ligation assay. Punctate staining (red) indicates a TGF-bRI-CD44
interaction as detected by the assay.
(D) Anti-CD3 and anti-CD28 activatedWT and Cd44–/– naive CD4+ T cells were stimulated with TGF-b or recombinant galectin-9 and TGF-bRI kinase activity was
determined. Data are representative of two independent experiments (A–C) or are pooled from three independent experiments (D) with nR 4 mice each group.
*p < 0.05 (Student’s t test, error bars represent SD).
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elevate under TGF-b stimulation at 12 hr. Such induction was
further enhanced with additional galectin-9 (Figure S6D). How-
ever, enhanced acetylated histone H4 was already detected
while Foxp3 mRNA didn’t increase at this time in the presence
of galectin-9 and TGF-b (Figure 6B, Figure S6D). These results
indicate that during the initial phase of iTreg cell differentiation,
histone modification could be accelerated by the presence
of galectin-9 signal, increasing the accessibility of the Foxp3
locus.
To determine the galectin-9 effect on Foxp3 promoter and/or
enhancer activity, we transfected EL4 LAF cells with Foxp3 lucif-
erase reporter constructs with or without the CNS1 enhancer re-
gion under different stimuli. The luciferase activity was higher in
the presence of exogenous galectin-9 than TGF-b alone and this
enhancementwasblockedbyananti-CD44 antibody (Figure 6C).
The synergistic effect of galectin-9 with TGF-b on promoting276 Immunity 41, 270–282, August 21, 2014 ª2014 Elsevier Inc.Foxp3 expression via CNS1 enhancer was also found to be
dose dependent (Figure S6E). Thereby, galectin-9 enhances
the binding affinity of Smad3 to the Foxp3 CNS1 region and fa-
cilitates the permissiveness of the Foxp3 enhancer, leading to
the upregulation of Foxp3 expression.
The CNS1 region has been reported to be critical in iTreg cell
generation. CNS1-deficient mice (Foxp3DCNS1) exhibit compara-
ble nTreg cells, while the number of TGF-b-dependent iTreg cells
is affected (Josefowicz et al., 2012b; Zheng et al., 2010). We
observed reduced Foxp3 expression in the Foxp3DCNS1 Treg
cells following in vitro differentiation with TGF-b. Addition of
galectin-9 enhanced the expression of Foxp3 in WT, but not
CNS1-deficient, T cells (Figure 6D). We further analyzed the
role of galectin-9 in the generation of iTreg and nTreg cells in vivo
by reconstituting congenicCD45.1WTorLgals9–/–hostmicewith
WT or Foxp3DCNS1 (CD45.2) BM. Ten weeks after reconstitution,
we observed a similar number of thymic nTreg cells in mice
Figure 6. CNS1 Region Is Essential for Galectin-9 Signaling within iTreg, but Not nTreg, Cells
(A) The binding of Smad3 and AcH4 to the Foxp3 CNS1 region from sorted GFP+ T cells of Figure S6C from Foxp3GFP and Foxp3GFPLgals9–/– iTreg cells was
determined by ChIP-PCR.
(B) The binding of AcH4 to the Foxp3 CNS1 region from activated naive T cells as in Figure S6D was determined by ChIP-PCR.
(C) EL4 LAF cells were transfectedwith a Foxp3 promoter construct with or without the CNS1 region and stimulated with anti-CD3 and anti-CD28 antibodies in the
presence of the indicated stimulations. Luciferase activity was measured 48 hr later. Data are representative of two independent experiments.
(D) Anti-CD3 and anti-CD28 activated naive CD4+ T cells from WT or Foxp3DCNS1 mice were stimulated with different combinations of TGF-b and recombinant
galectin-9 and the frequency of Foxp3+ cells was determined by flow cytometry.
(E) Chimeric mice were generated by transferring WT or Foxp3DCNS1 BM into WT or Lgals9–/– host mice. Ten weeks after reconstitution, the frequency of
Foxp3+Nrp1lo iTreg cells or Foxp3+Nrp1hi nTreg cells in PP and LPwas determined by flow cytometry. Data are pooled from three independent experiments (A–C)
or are representative of two independent experiments (D and E) with nR 4 mice each group. *p < 0.05 and **p < 0.01 (Student’s t test, error bars represent SD).
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of the Treg cell population in PP and LP showed that the lack of
the CNS1 region led to reduced development of iTreg cells in
both WT and Lgals9–/– hosts (Figures 6E and S6H). More impor-
tantly, the presence of galectin-9 had no effect on the frequency
of nTreg cells regardless of the presence of CNS1 (Figure 6E).
Both in vitro and in vivo analysis of CNS1-deficient T cells
confirmed that galectin-9 regulates the development of iTreg
cells by engaging the CNS1 enhancer region, which exclusively
regulates the development of iTreg, but not nTreg, cells.
Galectin-9-CD44 Interaction Regulates iTreg
Differentiation and Function
To illustrate whether the galectin-9 and CD44 interaction affects
the differentiation of iTreg cells, we treated T cells with an anti-CD44 blocking antibody during in vitro iTreg cell differentiation.
The synergistic effect of galectin-9 and TGF-b in inducing
Foxp3 expression was abrogated by anti-CD44 antibody treat-
ment (Figure 7A). Moreover, by utilizing CD44-deficient mice,
we observed that Foxp3 expression during iTreg cell differentia-
tion was attenuated (Figure 7B). Similar to Lgals9–/– iTreg cells,
the expression of different costimulatory molecules on Cd44–/–
iTreg cells was also reduced (Figure S7A). Lastly, nanostring
multiplex expression analysis of Lgals9–/– iTreg cells revealed
an overlap in the gene expression with Cd44–/– iTreg cells, and
their expression pattern was different from that of WT iTreg cells
(Figure 7C). In line with this observation, Cd44–/– iTreg cells dis-
played impaired suppressive capacity in vitro (Figure 7D) and
failed to suppress disease in a T cell-induced colitis model (Fig-
ures 7E and S7B and S7C). Together these genomic andImmunity 41, 270–282, August 21, 2014 ª2014 Elsevier Inc. 277
Figure 7. Galectin-9-CD44 Interaction Regulates iTreg Differentiation and Function
(A) Activated WT naive CD4+ T cells were stimulated with combinations of anti-CD44 antibody and recombinant galectin-9 with or without TGF-b for 3 days. The
frequency of Foxp3+ cells was determined by flow cytometry.
(B) Anti-CD3 and anit-CD28 activated naive CD4+ T cells from WT or Cd44–/– mice were stimulated with different combinations of TGF-b and recombinant
galectin-9 and the frequency of Foxp3+ cells was determined by flow cytometry.
(C) Heatmap displaying nanostring data as fold change of selected gene subsets in the experimental settings: Cd44–/– versus Lgals9–/– versus WT iTreg cells.
(D) Proliferation of naive CD4+ T cells in the presence of anti-CD3 and anti-CD28 and GFP+ (Foxp3+) iTreg cells from WT or Cd44–/– mice. Data shown are
presented as mean [3H]-thymidine incorporation (cpm ± SEM, performed in triplicate).
(E) Body weight ofRag2–/–mice transferredwithWTCD4+CD25CD45RBhi T cells with or withoutWT orCd44–/– Foxp3+ (GFP) iTreg cells. Data are representative
of three independent experiments with nR 5 mice each group. *p < 0.05 (Student’s t test, error bars represent SD).
Immunity
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and CD44 signaling pathways in inducing iTreg cells.
DISCUSSION
Galectins are conserved glycan-binding proteins, which play
various critical roles in both innate and adaptive immunity.
Galectin-9 is a tandem repeat-type galectin, expressed ubiqui-
tously in different tissues and cells in both humans and mice (Li
and Turka, 2010; Zhu et al., 2005). Galectin-9 functions in both
effector and regulatory phases of the immune response (Ander-278 Immunity 41, 270–282, August 21, 2014 ª2014 Elsevier Inc.son et al., 2007; Arikawa et al., 2010; Su et al., 2011; Wang
et al., 2009; Zhu et al., 2005). During inflammation, the produc-
tion of galectin-9 in vivo generates a microenvironment that
limits effector T cell responses. We and others have demon-
strated that galectin-9 negatively regulates Th1 cell responses
by binding to Tim-3, resulting in the induction of T cell apoptosis
and exhaustion (Chou et al., 2009; Zhu et al., 2005). The binding
of galectin-9 to Tim-3 on T cells induces intracellular Ca2+ flux
and activates caspase 1 or apoptosis signaling pathways (Bi
et al., 2008; Lu et al., 2007; Zhu et al., 2005). Further evidence
has suggested that exogenous galectin-9 also suppresses the
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work presented here shows that instead of crosslinking Tim-3,
galectin-9 contributes to the amplification of TGF-b signaling
by clustering the CD44 and TGF-bRI, to reinforce Foxp3
expression and stability, and is essential for iTreg-mediated
suppressor function. Thus, galectin-9 signaling regulates the
reciprocal balance of effector and regulatory T cells by not
only inducing T cell death or exhaustion in previously differenti-
ated effector T cells but also promoting the generation of
Foxp3+ regulatory T cells. Moreover, galectin-9 is induced by
IFN-g in inflamed tissue during Th1 cell responses. Galectin-9
in turn induces apoptosis of Th1 cells via Tim-3 and thus can
control inflammation (Pender et al., 1992; Zhu et al., 2005).
IFN-g-deficient mice exhibit exaggerated autoimmunity, which
is possibly caused by disruption of this regulatory feedback
loop (Ferber et al., 1996; Wang et al., 2006). We have shown
here that galectin-9-deficient iTreg cells are not as effective
as WT iTreg cells in suppressing effector T cell responses
in vitro and in vivo, suggesting that galectin-9 potentially acts
as an effector molecule that delivers the immunosuppressive ef-
fects of Treg cells. This effect might not be limited to only CD4+
T cells, but also influences other immune cells, such as restrain-
ing the CD8+ T cell response during viral infection (Sehrawat
et al., 2010). Therefore, galectin-9 could serve as part of a
signaling loop in effector T cells and Treg cells, balancing the
pro- and anti-inflammatory cell population and preventing pro-
tracted inflammation.
TGF-b signaling through the heterodimeric TGF-bRI-RII leads
to the activation of the Smad pathway, which is essential for the
induction of Foxp3 and development of Treg cells (Derynck and
Zhang, 2003). Unexpectedly, the Foxp3 promoter region con-
tains few TGF-b-responsive elements and therefore has only
limited influence on the induction of Foxp3 upon TGF-b stimula-
tion. Instead, the intronic enhancer I (CNS1) region, which con-
tains both NFAT and Smad3 binding sites, was determined to
be the more dominant regulatory site and largely controls the
expression of Foxp3 following TGF-b signaling (Tone et al.,
2008; Xu et al., 2010). It has been described that CNS1-deficient
mice exhibit dysregulated immune response on themucosal sur-
face, due to the iTreg cell deficiency, while Th1 and Th17 cells
are not altered (Josefowicz et al., 2012b; Katoh et al., 2007).
Although these phenotypes are similar to the Lgals9–/– mice,
we didn’t observe spontaneous inflammation in the intestines
of the Lgals9–/– mice. This might be due to the fact that CNS1-
deficient mice have almost a complete loss of iTreg cells while
galectin-9 acts ‘‘only as an’’ amplification factor of iTregs in the
presence of TGF-b. We found that the loss of galectin-9 causes
impaired Smad3 binding on the CNS1 region. Reporter assays
further showed that the CNS1 region was crucial for the
response to galectin-9 during iTreg cell differentiation. A recent
study provides unexpected data indicating that even though
Smad3 binding to CNS1 is critical for Foxp3 initiation in vitro,
the specific deletion of the Smad3-binding site from the CNS1
region in vivo has no impact on the development of nTreg cells
but has profound effects on the generation of iTreg cells in the
gut (Schlenner et al., 2012). Our results with CNS1 null mice sug-
gest that galectin-9 signaling acts dominantly through the CNS1
region of the Foxp3 locus, therefore specifically affecting the
generation of iTreg, but not nTreg cells.In vivo conversion of Treg cells into effector T cells has been
described in a setting of inflammation during a mouse diabetes
model (Zhou et al., 2009). In vitro generation of iTreg cells under
TGF-b stimulation has been employed in various studies. How-
ever, their suppressive capability has been debated. The unsta-
ble Foxp3 expression in the absence of continued TGF-b
signaling is one of the many reasons why iTreg cells can change
their phenotype during an immune response (Floess et al., 2007).
nTreg cells, on the other hand, have been shown to sustain
Foxp3 expression and suppressive function in vivo even in the
face of inflammation (Rubtsov et al., 2010). Here we observed
impact of galectin-9 deficiency on Foxp3 maintenance specif-
ically in iTreg cells, supporting the notion that an important func-
tion of galectin-9 is to stabilize iTreg cells. The expression of
Foxp3 alone is not sufficient to promote the stability and sup-
pressive capacity of the Treg cell lineage. It has been shown
that the epigenome-dependent programming is critical for deter-
mining the sustainability and fate of Treg cells (Floess et al.,
2007; Ohkura et al., 2012). We have shown that there is a reduc-
tion of histone acetylation in the Foxp3 locus in Lgals9–/– Foxp3+
iTreg cells. Galectin-9 signaling was further proved to be essen-
tial for initiating histone modification at the CNS1 site during
iTreg cells differentiation. These data therefore provide evidence
that galectin-9 promotes iTreg cell differentiation via increasing
the accessibility of the Foxp3 enhancer.
Tim-3 has been reported as a well-characterized receptor for
galectin-9 (Jayaraman et al., 2010; Reddy et al., 2011; Zhu
et al., 2005). The Tim-3-galectin-9 interaction induces signals
that can mediate Th1 cell apoptosis and inhibition of cytotoxic
T lymphocytes (CTL), leading to the attenuation of autoimmune
diseases and prolongation of allograft survival (Sehrawat et al.,
2010; Xu et al., 2010; Zhu et al., 2005). Even though it has
been reported that the Tim-3-galectin-9 interaction promotes
the suppressive activity of Treg cells and induces a higher fre-
quency of Treg cells during allogeneic skin grafts (Rabinovich
and Toscano, 2009; Wang et al., 2009), we found no Tim-3
expression on iTreg cells in vitro. Another known receptor for
galectin-9, CD44, is highly upregulated on activated T cells (Ka-
toh et al., 2007; Tanikawa et al., 2010). Its expression correlates
with the upregulation of Foxp3 and the suppressive function of
Treg cells (Liu et al., 2009). CD44 was reported to deliver a cos-
timulatory signal to Treg cells upon the activation of TCR (Bollyky
et al., 2009). Our data suggest that such a costimulatory signal
might be mediated by galectin-9-CD44 interaction. Moreover,
the fact that Lgals9–/– T cells show a specific defect in iTreg
cell differentiation, regardless of the ubiquitous expression of
CD44 in activated T cells, suggests that galectin-9 plays an indis-
pensable role in TGF-b signaling by bridging CD44 and TGF-bRI,
hence promoting iTreg cell differentiation. Moreover, we
observed a striking relatedness between the Lgals9–/– and
Cd44–/– iTreg cells at the level of cell phenotype, genetic signa-
tures, and functionality. These data therefore implicate the direct
interaction between galectin-9 and CD44 upon TGF-b stimula-
tion in regulating the development of iTreg cells.
In summary, we show here that galectin-9 promotes Foxp3
expression and stability upon TGF-b stimulation in iTreg cells.
Furthermore, our data demonstrate that during iTreg cell
differentiation, a CD44-TGF-bRI complex is responsible for
transducing the galectin-9 signal, which in turn increasesImmunity 41, 270–282, August 21, 2014 ª2014 Elsevier Inc. 279
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Gal9 Enhances Stability and Function of iTregsSmad3-driven Foxp3 transactivation. Therefore, galectin-9 ap-
pears to inhibit autoimmunity and induce tolerance by multiple
mechanisms, including inhibition of effector T cells by interacting
with Tim-3 and inducing iTreg cells via CD44-TGF-bRI. Consid-
ering the critical role of iTreg cells in autoimmunity and tissue
inflammation, the identification of a galectin-9-CD44 interaction
in iTreg development and function might offer potential targets
for inhibiting pathogenic immune responses and promoting pe-
ripheral tolerance.
EXPERIMENTAL PROCEDURES
Animals
C57BL/6 (B6), Cd44–/–, Rosa26RFP, Rag2–/–, and Rag2–/– OT-II mice were pur-
chased from Jackson Laboratory; Foxp3GFP, Foxp3Cre, Lgals9-Tg, Lgals9–/–,
Smad3–/–, and Foxp3DCNS1 mice have been described previously (Bettelli
et al., 2006; Datto et al., 1999; Seki et al., 2007; Tsuboi et al., 2007; Zheng
et al., 2009; Zheng et al., 2010). All experiments were carried out in accordance
with guidelines prescribed by the Institutional Animal Care andUse Committee
(IACUC) at Harvard Medical School.
T Cell-Induced Colitis
Naive (CD44loCD62L+GFP–) CD4+ T cells were purified from WT or Lgals9–/–
Foxp3gfp mice, as described above, and were then stimulated with plate-
bound anti-CD3 and anti-CD28 and 5 ng/ml TGF-b1 for 3 days. CD4+
CD25CD45RBhi naive T cells (7 3 105) were injected intraperitoneally (i.p.)
with or without in vitro differentiated and resorted WT or Lgals9–/– iTreg CD4+
Foxp3+ (1.53 105) into age- and sex-matched Rag2/mice, and weight loss
was monitored.
Statistical Analysis
Statistical analysis was performed with Prism software (Graph Pad software).
p values < 0.05 were considered significant.
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